M&As this week: First Coin Capital, China Grand Pharmaceutical and Healthcare Holdings, Tael Management
Canadian technology services company First Coin Capital plans to acquire Bradmer Pharmaceuticals, a pharmaceutical company based in the US.
First Coin plans to raise C$10m ($7.97m) through the private placement of subscription receipts to fund the acquisition.
China Grand Pharmaceutical and Healthcare Holdings (formerly Maxx Bioscience Holdings) plans to acquire 22.8% stake in Chinese pharmaceutical company Shanxi Xin Beilin Medical from Huang Xiaohua.
The purchase consideration for the acquisition is CNY131.5m ($19.76m).
Tael Management (Singapore) (TAEL Two Partners) and David Ho Sue San (collectively joint offerors) plan to acquire the remaining stake in Malaysian pharmaceutical company Hovid Berhad for MYR243m ($57.31m).
The Singapore-based private equity firm plans to make the acquisition through Fajar Astoria Sdn Bhd, a special purpose vehicle.
Biopharmaceutical company Ligand Pharmaceuticals plans to acquire antibody discovery company Crystal Biosciences for $25m.
Both companies involved in the acquisition are based in the US.